Javelin Pharmaceuticals, Inc. (JAV) posted fourth quarter net loss attributable to common stockholders of $8.1 million or $0.13 per share, compared to a net loss of $13.8 million or $0.23 per share in the year-ago quarter.
Total revenues for the quarter decreased to $301 thousand from $490 thousand in the last year quarter.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.09 per share on revenues of $550.00 thousand. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.